PDE5A and benign prostatic hyperplasia: As a long-lasting PDE5 inhibitor, it was also approved in 2009 by the US Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) [9,10,11,12] and for the treatment of lower urinary tracts symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) [13,14].